Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial

Fig. 2

Migraine Disability Assessment total score, by visit: (a) mean changes from baseline and (b) level of disability. Mean Migraine Disability Assessment total score at baseline: 56.8. The level of disability in daily functioning was graded using the Migraine Disability Assessment total score: 0–5 days, grade I (little or no disability); 6–10 days, grade II (mild disability); 11–20 days, grade III (moderate disability); 21+ days, grade IV (severe disability) [15]

Back to article page